Why aren't there medications to treat atherosclerosis or, more specifically, the underlying chronic inflammation of the blood vessel walls associated with this condition? Dr. Lawrence Cohen, president and CEO of VIA Pharmaceuticals, tells the Chicago Tribune's Bruce Japsen about the coming medications in U.S.-approved clinical trials to treat this inflammatory process.
Treatments for Cardiac Blood Vessel Inflammation In the Works

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Why aren't there medications to treat atherosclerosis or, more specifically, the underlying chronic inflammation of the blood vessel walls associated with this condition? Dr. Lawrence Cohen, president and CEO of VIA Pharmaceuticals, tells the Chicago Tribune's Bruce Japsen about the coming medications in U.S.-approved clinical trials to treat this inflammatory process.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?